SFDA Approves Marketing Authorization for Advanced Brain-Stimulation Medical Device for Parkinson's Disease

The Saudi Food and Drug Authority (SFDA) has approved the medical device marketing authorization (MDMA) for a device that uses advanced deep brain stimulation technology. The SFDA described this technology as a breakthrough in neurological therapy, as it enables physicians to adjust treatment procedures in real time based on live brain signals detected during therapy. This allows for the personalization of treatment using data and algorithms, adapting to the patient’s changing condition.

The SFDA clarified that the device functions by capturing and recording brain signals, allowing healthcare providers to modify stimulation settings in real time. Implanted in specific areas of the brain, the device contributes to the treatment of neurological conditions such as Parkinson’s disease by delivering programmable electrical pulses. These pulses are adjustable to precisely match the individual needs of each patient, helping to improve symptoms and reduce side effects. Additionally, the device is rechargeable, which minimizes the need for repeated surgeries to replace the battery.

These procedures are part of the SFDA’s ongoing efforts to implement its strategic objectives, which aim to enhance public health through the adoption of the latest global medical technologies and to provide innovative solutions for treating chronic diseases. This decision was made following a thorough scientific assessment of the device’s technical and clinical file, ensuring compliance with unified requirements and alignment with best international practices that match rapid and continuous technological advancements.